Skip to main
ATRC
ATRC logo

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure Inc. reported strong revenue growth of $124.3 million in Q4 2024, reflecting a year-over-year increase of 16.6%, with significant contributions from both its cardic ablation and pain management product lines. The company's R&D expenditure represented 28.1% of sales, which was notably higher than anticipated, driven by a substantial $12 million upfront payment for a co-development agreement, indicating robust investment in innovative product development. Furthermore, AtriCure's EBITDA margin improved to 10.2%, surpassing consensus estimates, highlighting efficient cost management and a favorable outlook for continued revenue expansion driven by new product launches and growing market demand.

Bears say

AtriCure Inc faces several fundamental challenges, including disappointing sales from key products and increasing market share loss to competitors, particularly with Medtronic's Penditure device impacting their left atrial appendage management segment. Revenue growth has decelerated, dropping to 17% in the fourth quarter of 2024 from 18% in the third quarter, driven by lower performances in minimally invasive ablation and appendage management. Additionally, the company has experienced declines in both gross margin and operating margin, with the gross margin at 74.5%, which fell short of expectations, signifying pressures from unfavorable product and geographic mix that may further hinder financial performance.

AtriCure (ATRC) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Buy based on their latest research and market trends.

According to 14 analysts, AtriCure (ATRC) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.